New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 30, 2013
18:48 EDTBX, GSKBlackstone, LIon Capital to bid for GSK's soft drinks, Sky News says
Blackstone (BX) and Lion Capital have teamed up to submit a formal bid for the two soft drinks Lucozade and Ribena, which have been put up for sale by drugmaker GlaxoSmithKline (GSK), says Sky News. Reference Link
News For BX;GSK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 30, 2015
08:37 EDTBXBlackstone forms utility and heavy equipment platform
Subscribe for More Information
05:52 EDTBXStocks with implied volatility movement; BRKB BX
Subscribe for More Information
January 29, 2015
07:20 EDTBXBlackstone reports Q4 ENI $1.25, consensus 93c
Reports Q4 revenue $2.14B, consensus $1.81B. At year end , total AUM was $290.3B, up 9% year-over-year. Fee-earning AUM $216.69B, up 9%.
06:43 EDTBXFTC issues subpoenas regarding Sysco, US Foods merger, NY Post says
Indicating further delays and possible cancellation of the deal, regulators from the Federal Trade Commission sent subpoenas to a third-party food distributor this week regarding Sysco's (SYY) $8.2B merger with US Foods, reports the New York Post, citing a source with direct knowledge of the situation. The source said it is "shockingly unclear" whether the FTC is gathering information in order to approve the deal or to block it. Blackstone's (BX) Performance Food Group, which earlier agreed to buy $5B of Sysco assets to make Sysco's merger more palatable to regulators, did not receive a subpoena. Reference Link
January 28, 2015
11:38 EDTGSKEC clears GlaxoSmithKline, Novartis deals, with conditions
Subscribe for More Information
09:06 EDTBXBlackstone announces partnership with Raider Hill Advisors
Subscribe for More Information
January 27, 2015
09:25 EDTBXBlackstone raises energy-sector credit fund, Reuters says
Subscribe for More Information
January 26, 2015
10:23 EDTBXBlackstone announces sale of Gold Fields House in Sydney
Subscribe for More Information
09:19 EDTGSKGlaxoSmithKline announces availability of two new products for asthma
Subscribe for More Information
07:55 EDTBXBlackstone to sell Sydney office building to Dalian Wanda, Reuters reports
Subscribe for More Information
January 23, 2015
09:38 EDTBXBlackstone acquires 160,000 SQM of logistics assets in Germany
Subscribe for More Information
08:52 EDTGSKArray BioPharma to hold a conference call
Subscribe for More Information
08:10 EDTGSKArray agrees to acquire rights to encorafenib
Array BioPharma (ARRY) announced that it has reached a definitive agreement with Novartis (NVS) to acquire worldwide rights to encorafenib, a BRAF inhibitor currently in Phase 3 development. This agreement is conditional on the closing of transactions announced by Novartis and GlaxoSmithKline (GSK) on April 22, 2014, which are expected to close in the first half of 2015, and the agreement remains subject to the receipt of regulatory approvals. Array previously announced a definitive agreement with Novartis to regain global rights to the Phase 3 MEK inhibitor binimetinib, the material terms of which remain in place following this agreement. In order to address competition concerns raised by the European Commission, Array has agreed to obtain an experienced partner for global development and European commercialization of both binimetinib and encorafenib. The European Commission is expected to issue a decision regarding the Novartis-GSK transaction on January 28, 2015. Upon satisfaction of all conditions and closing of the deal, Array will acquire global rights to encorafenib. Other than a de minimis payment due to Novartis from Array, there are no milestone payments or royalties payable under this agreement by either party. Novartis has agreed to provide transitional regulatory, clinical development and manufacturing services as specified below and will assign or license to Array all patent and other intellectual property rights Novartis owns to the extent relating to encorafenib. As part of the transaction, Array has agreed to obtain an experienced partner for global development and European commercialization of both binimetinib and encorafenib. If Array is unable to find a suitable partner in the prescribed time period, a trustee would have the right to sell such European rights. Novartis will conduct and fund the COLUMBUS trial through the earlier of June 30, 2016 or completion of last patient first visit. At that time, Array will assume responsibility for the trial, while Novartis will reimburse Array for out-of-pocket costs along with 50% of Array's full time equivalent costs in connection with completing the COLUMBUS trial. Novartis is responsible for conducting all other encorafenib trials until their completion or transfer to Array for a defined transition period. For all trials transferred to Array, Novartis will reimburse Array for out-of-pocket costs and 50% of Array's FTE costs in connection with completing the trials. Novartis will supply encorafenib for clinical and commercial use for up to 30 months after closing and will also assist Array in the technology and manufacturing transfer of encorafenib. Novartis will also provide Array continued access to several Novartis pipeline compounds for use in currently ongoing combination studies, and possible future studies, including Phase 3 trials, with encorafenib. The effectiveness of the agreement is subject to the receipt of regulatory approvals and to the consummation of the Novartis-GSK transaction. In addition, Array agreed to undertake to obtain certain third party consents or waivers necessary for Array to consummate the transactions under the Novartis Agreement.
07:44 EDTGSKGlaxo says now in position to deliver 'tens of thousands' of Ebola vaccine doses
Witty expects to start seeing data from trials of Ebola vaccines in next four to five months. GlaxoSmithKline CEO Andrew Witty speaking on CNBC.
06:39 EDTGSKNIH, GlaxoSmithKline, Merck launch joint Ebola vaccine test in Liberia, WSJ says
Subscribe for More Information
January 21, 2015
12:30 EDTGSKGlaxoSmithKline 'admired' by Pfizer CEO, FT reports
Subscribe for More Information
January 20, 2015
10:27 EDTBXSources: Blackstone to buy 36 apartment properties for $1.7B, Bloomberg reports
According to two sources, Blackstone will acquire 36 apartment properties across the U.S. that are being sold by Praedium Group for about $1.7B, Bloomberg reports. The properties, which contain about 11,000 apartments, are located in Washington, D.C., Boston, California and other cities. Reference Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use